- Home
- APVO vs LIXT Comparison
APVO vs LIXT Comparison
Compare APVO & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APVO
- LIXT
- Stock Information
- Founded
- APVO 2016
- LIXT 2005
- Country
- APVO United States
- LIXT United States
- Employees
- APVO N/A
- LIXT N/A
- Industry
- APVO Biotechnology: Pharmaceutical Preparations
- LIXT Biotechnology: Pharmaceutical Preparations
- Sector
- APVO Health Care
- LIXT Health Care
- Exchange
- APVO Nasdaq
- LIXT Nasdaq
- Market Cap
- APVO 4.4M
- LIXT 4.1M
- IPO Year
- APVO N/A
- LIXT N/A
- Fundamental
- Price
- APVO $4.50
- LIXT $1.90
- Analyst Decision
- APVO Strong Buy
- LIXT
- Analyst Count
- APVO 1
- LIXT 0
- Target Price
- APVO $296.00
- LIXT N/A
- AVG Volume (30 Days)
- APVO 485.4K
- LIXT 19.4K
- Earning Date
- APVO 11-07-2024
- LIXT 11-12-2024
- Dividend Yield
- APVO N/A
- LIXT N/A
- EPS Growth
- APVO N/A
- LIXT N/A
- EPS
- APVO N/A
- LIXT N/A
- Revenue
- APVO N/A
- LIXT N/A
- Revenue This Year
- APVO N/A
- LIXT N/A
- Revenue Next Year
- APVO N/A
- LIXT N/A
- P/E Ratio
- APVO N/A
- LIXT N/A
- Revenue Growth
- APVO N/A
- LIXT N/A
- 52 Week Low
- APVO $3.65
- LIXT $1.31
- 52 Week High
- APVO $399.60
- LIXT $4.40
- Technical
- Relative Strength Index (RSI)
- APVO 35.34
- LIXT 57.92
- Support Level
- APVO $3.65
- LIXT $1.85
- Resistance Level
- APVO $4.78
- LIXT $2.65
- Average True Range (ATR)
- APVO 1.95
- LIXT 0.18
- MACD
- APVO -0.70
- LIXT 0.03
- Stochastic Oscillator
- APVO 7.55
- LIXT 43.37
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.